Check-Cap stock (IL0010824143): merger with Keystone Dental and Nasdaq delisting reshape the story

Check-Cap is pursuing a reverse merger with US-based Keystone Dental, plans to delist from Nasdaq and discontinue its C-Scan cancer-screening capsule. The strategic shift moves the focus toward dental implants and prosthetics, raising new questions for investors.

Check-Cap, historically known for its C-Scan colorectal cancer-screening capsule, is in the midst of a radical strategic shift: the Israeli company has agreed to a reverse merger with US-based Keystone Dental, plans to delist its shares from Nasdaq and wind down its flagship diagnostics program, according to a joint press release dated March 13, 2024 and related SEC filings cited by Reuters as of 03/13/2024 and disclosures referenced by SEC filing as of 04/15/2024.

Under the merger terms, Keystone Dental shareholders are expected to own the majority of the combined company, which would operate primarily as a dental implants and prosthetics supplier rather than a colon-cancer screening specialist, according to the March 13, 2024 announcement summarized by Reuters as of 03/13/2024. Check-Cap has also indicated that development of C-Scan will be discontinued and that a significant workforce reduction is planned.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Check-Cap Ltd
• Sector/industry: Medical technology / dental implants (in transition)
• Headquarters/country: Isfiya, Israel
• Core markets: Historically gastroenterology diagnostics; future focus on dental implant and prosthetics markets, primarily in the United States and other developed regions
• Key revenue drivers: Before the merger: R&D-driven colorectal cancer screening technology; after the merger: dental implants, prosthetics systems and related solutions marketed by Keystone Dental
• Home exchange/listing venue: Nasdaq (planned delisting in connection with Keystone Dental merger, subject to closing)
• Trading currency: USD

Check-Cap: core business model

Check-Cap built its early-stage business model around C-Scan, a capsule-based system designed to detect colorectal polyps without the need for traditional invasive colonoscopy preparation. The company positioned this approach as a more patient-friendly screening method aimed at increasing participation in colorectal cancer prevention programs, according to company materials and prior regulatory filings discussed by Reuters as of 05/01/2023.

The business model, however, remained heavily dependent on clinical validation and regulatory milestones. Check-Cap had no large recurring commercial revenue base and instead relied on equity financing to fund its development activities, a common pattern in early-stage medtech companies focused on disruptive diagnostics technologies, as indicated in its historical annual reports referenced by company filings as of 04/15/2024.

The announced merger with Keystone Dental changes this structure substantially. Rather than depending on a single pre-commercial diagnostic asset, the combined company is expected to center on Keystone’s portfolio of dental implants and prosthetic solutions, which already generate revenue in multiple markets. This shifts Check-Cap from a high-risk, binary clinical development story toward a more traditional medical device commercial platform, according to the joint announcement summarized by Reuters as of 03/13/2024.

Main revenue and product drivers for Check-Cap

Before the Keystone Dental transaction, Check-Cap’s value proposition was tied almost entirely to C-Scan’s potential market penetration in colorectal cancer screening. The total addressable market in this area is large, particularly in developed healthcare systems such as the United States, where aging populations and prevention programs drive demand for more tolerable screening options, according to sector data from organizations like the American Cancer Society cited by Reuters as of 03/01/2023.

However, C-Scan remained in the development phase and had not yet unlocked broad reimbursement or regulatory approvals in key markets. As a result, Check-Cap generated limited operating revenues and regularly reported net losses, with cash burn rates that required periodic capital raises, according to its 2023 financial statements summarized in a Form 20-F filing referenced by SEC filing as of 04/15/2024.

Post-merger, the main revenue drivers are expected to come from Keystone Dental’s existing product lines. Keystone markets dental implant systems and prosthetics that are used by dentists and oral surgeons to replace teeth and restore function, primarily in North America and Europe. This portfolio gives the combined entity a foundation of recurring product sales, which differs markedly from Check-Cap’s earlier dependence on a single, unproven diagnostic technology, as described in the March 13, 2024 transaction announcement covered by Reuters as of 03/13/2024.

For investors, this shift in revenue mix also implies different risk factors. Dental implants operate in a competitive but established medical device market with multiple global players, whereas early-stage cancer diagnostics involve high scientific uncertainty but potentially transformational upside if clinical performance and reimbursement align. The Keystone transaction effectively tilts the balance toward commercial execution risk rather than binary development outcomes.

Strategic rationale: from cancer screening to dental implants

The decision to pursue a reverse merger and discontinue C-Scan development stemmed in part from strategic reviews of Check-Cap’s options after challenging clinical and funding conditions. The company had previously explored alternatives including partnerships, licensing and broader corporate transactions in response to capital market headwinds, according to a review process described in a May 2023 update cited by Reuters as of 05/01/2023.

By aligning with Keystone Dental, Check-Cap gains access to a commercial-stage business with an established sales network and product pipeline. Keystone, in turn, obtains a public listing vehicle, which can offer additional financing options and visibility in the US capital markets, even if the combined company ultimately trades on an over-the-counter market following the planned Nasdaq delisting, as suggested by details in the transaction filings referenced by SEC filing as of 04/15/2024.

The transaction structure, where Keystone shareholders will hold a majority stake, makes clear that Keystone’s assets and management will dominate the combined entity’s strategic direction. For existing Check-Cap shareholders, the deal effectively converts exposure from an R&D-driven colorectal screening project into a minority position in a dental implants specialist, shifting both the industry profile and the geographic revenue mix more toward the US and other developed dental markets.

Nasdaq delisting risk and capital market implications

A key element of the Keystone Dental merger story is the planned delisting of Check-Cap shares from Nasdaq in connection with the combination. Check-Cap had previously faced Nasdaq compliance challenges, including minimum bid price requirements, which are common issues for small-cap biotech and medtech companies trading below certain thresholds, according to regulatory notices discussed in its exchange correspondence summarized by Nasdaq filings as of 04/15/2024.

Upon closing of the reverse merger, the combined company is expected to delist from Nasdaq and may continue trading on an alternative venue or as a privately held entity, depending on the final structure. Such moves can affect liquidity, visibility and index inclusion, all of which are relevant for institutional and retail investors who track US-listed healthcare stocks, as noted in transaction summaries covered by Reuters as of 03/13/2024.

For US-based investors, a delisting from Nasdaq typically means reduced trading volume and potentially wider bid-ask spreads. In addition, some brokerage platforms and investment mandates restrict or prohibit trading in over-the-counter securities, which can limit the investable universe. This is particularly relevant for smaller healthcare names where institutional ownership is sensitive to listing status and liquidity conditions, as highlighted in broader market analyses referenced by Reuters as of 10/12/2023.

Why Check-Cap matters for US investors

Although Check-Cap is headquartered in Israel, its historical and future relevance for US investors is significant. The company’s shares have traded on Nasdaq, a core venue for US retail and institutional investors seeking exposure to innovative healthcare names. The shift toward a dental implants business via Keystone Dental concentrates the combined company’s commercial presence even more in North America, including the United States, where dental procedures and implant adoption rates are comparatively high, according to sector data cited by Reuters as of 01/19/2024.

For US investors, this means that the underlying business risk will be tied less to regulatory approvals for a novel diagnostic device and more to factors such as competitive dynamics in the dental market, pricing power with dentists and distributors, and macroeconomic influences on elective or semi-elective dental procedures. Consumer confidence and employment trends in the US, which affect insurance coverage and discretionary spending, can influence volumes in dental implants and related restorative treatments, as highlighted in healthcare spending analyses reported by Reuters as of 12/13/2023.

In addition, the company’s transition from a development-stage medtech stock to a revenue-generating dental device platform alters how it may fit into diversified portfolios. Investors focused on high-risk, high-reward biotech-style opportunities might view the loss of C-Scan exposure as reducing upside potential, while those interested in more predictable device revenues could see the new profile as more aligned with their preferred risk-return mix, depending on final transaction terms and execution.

Conclusion

Check-Cap’s story has shifted from a speculative bet on a capsule-based colorectal cancer screening technology to a proposed reverse merger with Keystone Dental and an associated Nasdaq delisting. The combined company is expected to focus on dental implants and prosthetics, replacing binary clinical trial risk with commercial execution risk in a competitive, established medical device segment. For US investors, the transition alters the balance between innovation-driven upside and more traditional device-market dynamics, while the potential move away from Nasdaq may affect liquidity and accessibility. How this strategic pivot ultimately plays out will depend on closing conditions, integration progress and the ability of the Keystone Dental platform to compete effectively in key markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.